Adial Pharmaceuticals secures FDA support for AD04 as Phase 3 clinical trials move forward

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company specializing in addiction treatment development, has received a pivotal endorsement from the U.S. Food and Drug Administration (FDA) regarding its proposed in vitro bridging strategy for AD04. This regulatory approval pathway confirmation marks a significant milestone for the company as it prepares to advance its lead inves